Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests

EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure

“…). Outcomes were good, particularly related to tolerability and compliance, consistent with the results of the ESLIBASE study 27 and the report by Ley et al35 In our group, the dose ratios used are very similar to those recommended by Peltola et al36 : from oxcarbazepine to ESL was 0.9:1 (1:1 recommended byPeltola et al) and from carbamazepine to ESL was 1:1.3 (same as recommended byPeltola et al).…”

“…We attribute this improvement in compliance with the once-daily dosing of ESL. Outcomes were good, particularly related to tolerability and compliance, consistent with the results of the ESLIBASE study 27 and the report by Ley et al35 In our group, the dose ratios used are very similar to those recommended by Peltola et al36 : from oxcarbazepine to ESL was 0.9:1 (1:1 recommended byPeltola et al) and from carbamazepine to ESL was 1:1.3 (same as recommended byPeltola et al).A recent report demonstrated safe overnight switch from twice daily oxcarbazepine to once-daily ESL in 21 patients with epilepsy, resulting in immediate improvement of oxcarbazepine peak dose-related adverse events 37. One large study showed that the likelihood of a breakthrough seizure after a missed AED dose was higher with a higher dosing frequency: each increase in dose frequency (from one to four doses per day) increased the risk of a seizure after a missed dose by 36% 10.…”

Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli

“…The Euro-Esli study was an exploratory, retrospective, pooled analysis of data from European clinical practice studies, [9][10][11][12][13][14][15][16][17][18][19][20][21] conducted to audit the effectiveness, safety, and tolerability of ESL as an adjunctive treatment for focal-onset seizures in clinical practice, details of which have been published previously. 8 In brief, effectiveness was assessed after 3, 6, and 12 months of ESL treatment and at final follow-up, and safety and tolerability were assessed for the duration of ESL treatment.…”

Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy

“…It is of note that the threshold for clinically significant hyponatremia is not clear-cut, and that different thresholds are used in different settings. For example, publications have defined hyponatremia as [Na + ] <125 mEq/L (in line with this analysis), 27,29 ≤132 mEq/L, 30 ≤134 mEq/L (with severe hyponatremia defined as ≤128 mEq/L), 6,31 <135 mEq/L, 32 and <137 mEq/L. 33 Therefore, comparisons of hyponatremia rates across studies should be interpreted with caution.…”